Arcutis Biotherapeutics announces new Zoryve data at EADV congress

Arcutis Biotherapeutics (ARQT) announced that new data on Zoryve efficacy across three common skin conditions-seborrheic dermatitis, atopic dermatitis, and psoriasis-will be presented at the 34th Annual European Academy of Dermatology and Venereology Congress, which is taking place September 17-20 in Paris. A new subgroup analysis from the STRATUM study further highlights the efficacy of Zoryve foam 0.3% in individuals with diverse skin types, across ethnicity, race, and Fitzpatrick skin type. The data demonstrated: significant improvement in signs and symptoms of seborrheic dermatitis with Zoryve foam 0.3%, as measured by Investigator Global Assessment Success at Week 8 compared with vehicle, was reported for the overall population, with similar responses across subgroups by race, ethnicity and FST. Zoryve foam 0.3% improved itch, as measured by Worst Itch-Numeric Rating Scale Success at Week 8 compared with vehicle, in the overall patient population and across the subgroups by race, ethnicity and FST. A higher proportion of participants in the Zoryve foam 0.3% treatment group experienced no erythema and no scaling at Week 8 compared with vehicle in the overall patient population and among subpopulations. The safety and tolerability of Zoryve foam 0.3% were previously confirmed in the STRATUM Phase 3 study. Among all participants in the Zoryve foam 0.3% and vehicle treatment groups with hypopigmentation and hyperpigmentation at baseline, improvement was seen across all subgroups: 57.1% of White participants and 87.5% of Black/African American participants achieved partial or full resolution of hypopigmentation, and 75% of White participants and 60% of Black/African American participants achieved partial or full resolution of hyperpigmentation.